Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNABW) Treasury Shares (2019 - 2025)

Historic Treasury Shares for Ginkgo Bioworks Holdings (DNABW) over the last 7 years, with Q3 2025 value amounting to $4.7 million.

  • Ginkgo Bioworks Holdings' Treasury Shares rose 1412.04% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 1412.04%. This contributed to the annual value of $3.3 million for FY2024, which is 1255.41% down from last year.
  • As of Q3 2025, Ginkgo Bioworks Holdings' Treasury Shares stood at $4.7 million, which was up 1412.04% from $5.0 million recorded in Q2 2025.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Treasury Shares peaked at $254.3 million during Q3 2021, and registered a low of $3.3 million during Q4 2024.
  • Moreover, its 5-year median value for Treasury Shares was $168.8 million (2023), whereas its average is $131.3 million.
  • In the last 5 years, Ginkgo Bioworks Holdings' Treasury Shares surged by 3473.06% in 2021 and then tumbled by 9827.6% in 2025.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Treasury Shares (Quarter) stood at $168.3 million in 2021, then decreased by 20.13% to $134.4 million in 2022, then tumbled by 97.17% to $3.8 million in 2023, then dropped by 12.55% to $3.3 million in 2024, then soared by 39.86% to $4.7 million in 2025.
  • Its Treasury Shares stands at $4.7 million for Q3 2025, versus $5.0 million for Q2 2025 and $4.1 million for Q1 2025.